Reactive Arthritis (ReA) Diagnostic Criteria
Diagnoses reactive arthritis (formerly Reiter syndrome) using clinical triad and preceding infection evidence. Guides NSAID, antibiotic, and disease-modifying therapy.
Score interpretation
→ Investigate for alternative cause; joint aspiration to exclude septic arthritis and crystals; consider Lyme disease, viral arthritis; ANA, rheumatoid factor, anti-CCP
→ NSAIDs (naproxen 500mg BD or diclofenac 50mg TDS); treat active infection if still present (azithromycin/doxycycline for Chlamydia); intra-articular steroid for single joint; rheumatology referral
→ NSAIDs + local steroid injections; if persistent >3 months: sulfasalazine 500mg increasing to 1g BD; HLA-B27 if not tested; ophthalmology for uveitis; screen and treat sexual contacts if Chlamydia; check HIV
Interpretation bands for the Reactive Arthritis. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Hydroxychloroquine · Aminoquinoline — Malaria Prophylaxis / SLE / Rheumatoid Arthritis
- Azithromycin (Chlamydia / STI in Pregnancy) · Macrolide Antibiotic — STI Treatment
- Fluorescein Sodium 2% Eye Drops · Diagnostic ophthalmic dye
- Indocyanine Green (Intravitreal Chromovitrectomy) · Diagnostic Dye — Vitreoretinal Surgery / ICG Angiography
- Fluorescein sodium · Ophthalmic diagnostic dye
- Fluorescein with lidocaine · Topical anaesthetic + diagnostic dye
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.